DiaMedica Therapeutics (NASDAQ:DMAC) Receives New Coverage from Analysts at Craig Hallum

Craig Hallum began coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm issued a buy rating and a $8.00 price objective on the stock.

Separately, Oppenheimer reiterated an outperform rating and set a $6.00 price objective (down from $7.00) on shares of DiaMedica Therapeutics in a research note on Thursday, March 21st.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ DMAC opened at $2.45 on Wednesday. The business has a fifty day simple moving average of $2.81 and a 200 day simple moving average of $2.70. DiaMedica Therapeutics has a one year low of $1.50 and a one year high of $4.75.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). Analysts predict that DiaMedica Therapeutics will post -0.69 earnings per share for the current year.

Institutional Trading of DiaMedica Therapeutics

Several large investors have recently made changes to their positions in DMAC. Stonebridge Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics during the third quarter worth $52,000. Avantax Advisory Services Inc. bought a new stake in shares of DiaMedica Therapeutics during the fourth quarter worth $36,000. Finally, Paragon Associates & Paragon Associates II Joint Venture grew its holdings in shares of DiaMedica Therapeutics by 6.4% during the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock worth $1,420,000 after purchasing an additional 30,000 shares during the last quarter. Institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.